Perlmutter Cancer Center at NYU Langone Health· @Perlmutter_CC · X·· 1 天前评分45
正文 · 原文
Today at #ESMO2026, PCC’s Kristen Spencer, DO, (@kspencer725) presents research on novel targeted therapies for colorectal cancer, including KRAS G12D inhibitors and treatment approaches for MCC CRC.
@myESMO @nyugrossman
4 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org